Introduction {#Sec1}
============

Patients admitted to internal medicine wards with cardiorespiratory symptoms can be difficult to assess and treat as they are usually older, have multiple co-morbidities, and take multiple medication. Traditionally, internal medicine physicians rely on the medical history and physical examination, collectively known as the clinical evaluation, to derive a differential diagnosis and formulate an initial management plan. However, it has been reported that clinical evaluation alone is frequently inaccurate in determining the correct diagnosis \[[@CR1]--[@CR4]\]. The delay of making a precise diagnosis and starting an appropriate management could be detrimental for patient outcome. Further management is refined by investigations including medical imaging to confirm or rule out the differential diagnosis. However, unnecessary investigations can be associated with high cost and patient risk such as radiation exposure, contrast-induced nephropathy, and transfer of acutely ill patients to an investigation laboratory.

Ultrasonography has been used in medicine for at least 50 years, is non-invasive and without ionizing radiation. Only in the last two decades have ultrasound machines evolved to produce portable, low-cost units that are readily available for use at the bedside, facilitating its clinical uptake. The terms "clinical ultrasound" and "point-of-care ultrasound" (POCUS) are used to describe a bedside ultrasound examination performed by the treating doctor, as an adjunct to clinical evaluation \[[@CR5]\]. Its use has become very common in some medical specialties such as emergency medicine, anesthesia, and critical care. Several prior studies have demonstrated validity and reliability \[[@CR6]--[@CR14]\]. The organ scanned depends on the clinical question. By detecting omitted abnormalities in the physical examination \[[@CR1], [@CR2], [@CR4]\] and improving the hemodynamic status evaluation \[[@CR15], [@CR16]\], heart POCUS has become a useful tool in the evaluation of undifferentiated shock, guiding resuscitation, or as part of the preoperative evaluation in patients undergoing surgery \[[@CR17]--[@CR21]\] Furthermore, lung ultrasound has proved to be superior than physical examination and chest X-ray diagnosing pneumonia, interstitial syndrome (including pulmonary edema), and pleural effusion \[[@CR22], [@CR23]\]. In the emergency department and critical care setting, it is now frequently used in the approach of patients with dyspnea, in which lung POCUS alone or in combination with heart POCUS has demonstrated to be very precise distinguishing the primary cause \[[@CR24]--[@CR34]\].

Studies quantifying clinical impact of POCUS have shown that its use led to change diagnosis and modify management plans in 30%--80% of the cases depending on the clinical scenario \[[@CR17], [@CR18], [@CR35]--[@CR38]\]. Most of these studies have investigated imaging of one particular organ \[[@CR17], [@CR35], [@CR39]--[@CR42]\]. However, a multi-organ approach may better align with the initial assessment of complex cases in internal medicine as they are frequently multi-organ in presentation \[[@CR5], [@CR43]\]. This is especially true among cardiopulmonary patients in which a broad range of differential diagnoses can be proposed \[[@CR44]\]. In these patients, a combined heart and lung POCUS can identify the cause of dyspnea in most of the cases or significantly narrow the range of diagnoses \[[@CR26], [@CR33], [@CR34]\]. In addition to heart and lung POCUS, lower extremity vein POCUS can be used to accurately identify proximal deep venous thrombosis (DVT) \[[@CR12], [@CR45]\], which might cause pulmonary embolus and be the cause of shortness of breath or cardiovascular collapse. A multi-organ POCUS of the heart, lungs, and lower extremity veins has already been tested in a randomized trial with respiratory patients from the emergency department, reporting superiority of POCUS to standard diagnostic tests alone for establishing a correct diagnosis within 4 h \[[@CR27]\].

We expect that the addition of a heart, lung, femoral, and popliteal vein POCUS in cardiopulmonary patients admitted to internal medicine wards will have a positive impact in the timely diagnosis formulation and impact on decision-making. Moreover, it is plausible that improving diagnosis and altering management plans may lead to improvement in the workflow and reduction of the length of hospital stay.

Objectives and hypothesis {#Sec2}
-------------------------

The primary aim of the study is to determine whether a heart, lung, and lower extremity vein POCUS reduces the length of hospital stay of patients admitted to internal medicine wards with a cardiopulmonary diagnosis by \> 24 h.

The secondary aims are to evaluate the impact of POCUS on: (1) change in diagnosis and management plan; (2) 30-day hospital readmission; and (3) in-hospital health costs.

Trial design {#Sec3}
------------

The IMFCU-1 trial is a single-center, prospective, randomized, parallel group, unblinded, superiority trial with 1:1 allocation ratio. The intervention is a bedside ultrasound examination, which makes blinding not feasible.

Methods {#Sec4}
=======

Ethics approval for the study was obtained from Melbourne Health Human Research Committee on 27 June 2018 (protocol reference 2018.200). The study has been conducted in accordance with the Declaration of Helsinki and registered with the Australian and New Zealand Clinical Trial Registry on 28 August 2018 (ACTRN12618001442291). Table [1](#Tab1){ref-type="table"} in shows all the items of the World Health Organization trial registration dataset. Table 1World Health Organization trial registration dataset for IMFCU-1Data categoryInformationPrimary registry and trial identifying numberAustralian and New Zealand Trial Registration, ACTRN12618001442291Date of registration28 August 2018Prospective registrationYesPrimary sponsorRoyal Melbourne HospitalPublic titleA bedside ultrasound in general medicine patients with cardiopulmonary diagnosisScientific titleA randomized trial of focused cardiac, lung, and femoral and vein ultrasound on the length of stay in internal medicine admissions with a cardiopulmonary diagnosis. IMFCU-1 study.Date of first enrolment3 September 2018Target sample size250Recruiting statusRecruiting (103 recruited)URLU111112185271Study typeInterventionalStudy designRandomized controlled trial parallelPhaseNot applicableCountry of recruitmentAustraliaContactsProf Colin Royse (principal investigator)Address: Level 6, Centre of Medical Research, Royal Parade, Parkville, VIC 3052, Australia.Telephone: (61)383445673Email: colin.royse\@heartweb.comAffiliation: Department of Surgery, University of MelbourneDepartment of Anesthesia and Pain Management, Royal Melbourne HospitalKey inclusion & exclusion criteriaInclusion criteria:Adult patients (aged 18 years or older) admitted to general medicine unit at the Royal Melbourne Hospital with a cardiopulmonary diagnosis, expected to remain in hospital longer than 24 h.Exclusion criteria:Already admitted longer than 24 hAdmitted for social reasons rather than medicalHave received an echocardiography within four weeks before admission or a CT chest scan during the admission process before enrolmentHealth conditions or problems studiedHeart failure, asthma, COPD, pneumonia, PE, unspecified dyspneaInterventionA bedside ultrasound done by a physician trained in POCUS. The ultrasound takes around 20 min to be performed. The quality of the report will be assessed by a second expert who will check the images and videos recorded.Primary outcomeLOS at the hospitalSecondary outcomeIncidence of new diagnosis and Incidence of changing management. These two outcomes will be assessed only in the interventional group. The treating physician will be asked to fill in a form with the initial diagnosis and plan of management. This form is a checklist describing further investigations (blood test and imaging), consultation to another specialist and medication prescribed (diuretics, antibiotics, etc.). After performing and revealing to them the findings of the bedside ultrasound, the treating physician will be asked to fill a second form that is exactly the same than the first one. The difference between both will be analyzed as "change of management" due to our intervention.Health costs: this outcome will be assessed by the sum of the following three components: (1) cost per day at the hospital; (2) cost of the pathology investigation; (3) cost of the imaging tests.*COPD* chronic obstructive pulmonary disease, *IMFCU* internal medicine focused clinical ultrasound, *LOS* length of stay, *PE* pulmonary embolism, *POCUS* point-of-care ultrasound

Methods are reported in accordance with the Guidance for protocols of clinical trials (SPIRIT) \[[@CR46]\]. The SPIRIT checklist is shown in Additional file [1](#MOESM1){ref-type="media"}.

Study setting {#Sec5}
-------------

The trial is performed at the Royal Melbourne Hospital (RMH), a tertiary, public, university-affiliated teaching hospital, with 706 beds located in Victoria, Australia. Participants are recruited from the internal medicine wards, which are logistically divided into long-stay and short-stay units containing around 68 and 32 beds, respectively. Approximately 30% of the internal medicine patients are hospitalized due to cardiopulmonary conditions.

Eligibility criteria {#Sec6}
--------------------

Patients admitted to the internal medicine ward with a preliminary cardiopulmonary diagnosis are invited to participate in the study. Eligible participants are selected every workday morning by internal medicine physicians during their handover. After presenting the new cases, physicians are asked to identify the cardiopulmonary cases. For the purpose of the study, a cardiopulmonary diagnosis has been defined as a medical suspicion that the main health problem of the patient is related to one of the following heart or lung conditions: heart failure; acute coronary syndrome; pulmonary embolism (PE); pneumonia; decompensated chronic pulmonary obstructive disease; asthmatic crisis; cardiogenic syncope; interstitial pulmonary disease; cardiac valve disease; pleural effusion; or pericardial effusion.

### Inclusion criteria {#Sec7}

Age ≥ 18 years;Less than 24 h since admission to the internal medicine ward;Cardiopulmonary diagnosis defined by an internal medicine specialist.

### Exclusion criteria {#Sec8}

Previous echocardiography during the four weeks before hospital admission;Computed tomography chest during the current hospital admission;Requiring infectious disease isolation (contact, drops, or respiratory precaution);Unable to consent (by themselves or a third person who is nominated/identified as their next of kin).

Intervention {#Sec9}
------------

The intervention is a POCUS performed by an internal medicine physician with previous experience in POCUS and the certification of iHeartScan, iLungScan, and Focused Cardiac Ultrasound courses from the Educational Ultrasound Group of the University of Melbourne (XC).

POCUS is performed with an X-Porte portable ultrasonography machine (Sonosite, Bothwell, Andover, MA, USA) using a 1--5-MHz transthoracic and 6--13-MHz linear ultrasound probes. The ultrasound is performed at the patient's bedside, taking an average of 20 min to be completed.

Assessment of the heart and lungs is performed based on the iHeartScan and iLungScan protocols designed and validated by the Ultrasound Education Group of the University of Melbourne \[[@CR47]--[@CR49]\]. Heart structure and function are assessed using two-dimensional (2D) images and color flow Doppler; spectral Doppler is not included in this study to facilitate timely completion of the ultrasound and to increase its reproducibility. Heart POCUS involves four anatomical windows to record eight views (Fig. [1](#Fig1){ref-type="fig"}): parasternal long axis; right ventricle (RV) inflow; parasternal short axis at the level of the aortic valve; parasternal short axis at the level of the papillary muscle; apical four chambers (A4C); apical five chambers; subcostal four chambers; and subcostal inferior vena cava. Fig. 1Ultrasonography windows assessed in heart POCUS. Four anatomical windows are used to assess eight views of the heart: (1) At the level of the fourth intercostal space lateral to the left border of the sternum, PLAX and RV inflow are recorded. (2) The second window is technically the same than the first, from PLAX the probe is rotated in clock direction ending in the PSAX. Two views are recorded at this point, one at the level of the aortic valve and other at the level of papillary muscle or mid left ventricle. (3) Apical window is found about the fifth intercostal space between the mid clavicular line ant the anterior axillary line. In this window the views assessed are A4C and apical five-chamber. (4) Subcostal window involves two views: subcostal four-chamber view of the heart and the IVC view where the IVC can be identified ending in the right atrium. A4C, apical four chambers, IVC inferior vena cava, PLAX parasternal long axis, POCUS point-of-care ultrasound, PSAX parasternal short axis, RV right ventricle

The following variables are assessed and reported: volume and systolic function of the LV and RV; left atrial filling pressure based on the interatrial septum movement; significant regurgitation or stenosis of the valves; presence or absence of pericardial effusion; and diameter and collapsibility of the inferior vena cava. Definitions for each variable abnormality are summarized in Table [2](#Tab2){ref-type="table"}. A final statement about the hemodynamic condition will be written as follows: normal; hypovolemia; vasodilated; primary systolic dysfunction; primary diastolic dysfunction; systolic and diastolic dysfunction; and/or RV dysfunction as described by Royse et al. \[[@CR15]\] and summarized in Table [3](#Tab3){ref-type="table"}. Table 2Variables assessed and definitions of abnormality findings in heart POCUSVariable assessedDefinitionsLV volumeLVEDDNormal LVEDD 3--5.6 cmLV dilated \> 5.6 cmHypovolemia \< 3 cmLV systolic functionOverall subjective impressionNormal -- Reduced -- IncreasedDifference between diameters in diastole and systole (LVEDD--LVESD) in PLAX viewNormal 28--44 mmReduced \< 28 mmIncreased \> 44 mmDifference between areas in diastole and systole(LVEDA--LVESA) in PSAX viewNormal 50--65 mm^2^Reduced \< 50 mm^2^Increased \> 65 mm^2^RV sizeCompared to LV sizeNormal \< 2/3 of LV sizeRVEDDNormal \< 4 cmIncreased \> 4 cmRV systolic functionOverall subjective impressionNormal -- DecreasedLA sizeLA diameter in PLAX or A4C viewsNormal \< 3.5 cmLA area in A4C viewNormal \< 20 cm^2^Increased \> 20 cm^2^LA filling pressureInter-atrium septum movementNormal: systolic reversal of the inter-atrium septumHigh filling pressure: fixed curvature of the inter-atrium septum to the rightLow filling pressure: systolic buckling of the inter-atrium septumCardiac valvesLeaflets appearance and thicknessOpening of the valvePresence of reverse jetSignificant aortic stenosis:An opening \< 1.5 cm in PLAX orHeavy calcification with inability to see the valve openingSignificant aortic regurgitation:A jet that runs on the wall of the LV outflow trackA jet that is wider than 25% of the diameter of LVOTA jet that extends down to the ventricle \> 2.5 cmSignificant mitral stenosis:Impaired opening of the mitral valveA hockey stick appearance of one or both of the mitral leafletsSignificant mitral regurgitation:Regurgitation jet covering \> 20% of the LA area in A4C or PLAXA turbulent jet that runs along the wall of the atriumProminent flail mitral valve leaflet or rupture papillary muscleSignificant tricuspid regurgitation:Any edge-tracking jetAny central jet \> 5 cm^2^Pericardial effusionPresence of anechoic space between parietal and visceral pericardiumSignificant pericardial effusion is defined as \> 0.5 cm in any viewInferior vena cavaDiameter of the inferior vena cava in the subcostal view during normal breathingMaximum diameter in cm and percentage of collapsibility during normal inspiration are reported. Estimation of the right atrium pressure is informed as follows:IVC \< 2.1 cm collapsing \> 50% ➔ RAP: 3 mmHgIVC \> 2.1 cm collapsing \< 50% ➔ RAP: 15 mmHgValues between the two above ➔ RAP:8 mmHg*A4C* apical four chambers, *LA* left atrium, *LV* left ventricle, *LVEDA* left ventricle end-diastole area, *LVEDD* left ventricle end-diastole diameter, *LVESA* left ventricle end-systole area, *LVESD* left ventricle end-systole diameter, *PLAX* parasternal long axis, *POCUS* point-of-care ultrasound, *PSAX* parasternal short axis, *RAP* right atrium pressure, *RVEDD* right ventricle end-diastole diameter Table 3Hemodynamic state definitionsNormalHypovolemiaVasodilatedPrimary systolic failurePrimary diastolic failureSystolic and diastolic failureRV failure^a^LV volumeNormalDecreasedNormalIncreasedNormal/decreasedIncreasedRV increasedLV systolic functionNormalNormal/DecreasedIncreasedDecreasedNormalDecreasedRV decreasedLA filling pressureNormalDecreasedNormalNormalIncreasedIncreasedIncreasedHemodynamic state is defined based on LV volume, LV systolic function, and LA filling pressure^a^ RV failure can be a hemodynamic state by itself or in combination with LV failure*LA* left atrium, *LV* left ventricle, *RV* right ventricle

The lungs are scanned by division into three anatomical zones as previously reported by Ford et al. \[[@CR49]\] (Fig. [2](#Fig2){ref-type="fig"}). The anterior zone goes from the sternum edge to the mid-axillary line posteriorly; the upper posterior zone is defined by the mid-axillary line anteriorly, the spinous processes of the thoracic spine posteriorly, and the inferior tip of the scapular inferiorly: and the lower posterior zone is defined by the mid-axillary line anteriorly, the spinous process of the thoracic spine posteriorly, and the inferior rip of the scapula superiorly. Abnormal findings are recorded as: collapse; consolidation; alveolar/interstitial syndrome; pneumothorax; and/or pleural effusion. Definitions are described in Table [4](#Tab4){ref-type="table"}. Normal lung pattern is defined as the presence of normal lung sliding, reverberation artefacts from the pleural, and absence of any of the pathologies described. Fig. 2Anatomical zones scanned in lung POCUS. Illustrations of the front (*left*) and back (*right*) of the chest showing the six anatomical zones scanned. LA left anterior, LPL left posterior lower, LPU left posterior upper, POCUS point-of-care ultrasound, RA right anterior, RPL right posterior lower, RPU right posterior upper Table 4Definitions of ultrasound lung abnormalitiesAbnormal lung patternsDefinition / ultrasound findingsAlveolar/Interstitial syndrome3 or more B-lines in a single rib spaceB-lines were defined as hyperechoic, vertical artifacts arising from the pleural line and reaching the bottom of the screen without fadingCollapse or atelectasisLoss of lung volume, increased tissue density, and hyperechoic static air bronchogramsConsolidationTissue-like pattern or "hepatization" with minimal volume loss and the presence of dynamic air bronchogramsPneumothoraxAbsence of lung sliding and lung pulsePleural effusionAnechoic space between the parietal and visceral pleura with movement with the respiratory cycle. Significant pleural effusion is defined as \> 1 cm. An estimation of the volume of a pleural effusion in milliliters (ml) will be done multiplying by 200 the distance in cm in the vertical plane from the diaphragm to the inferior lung border at the junction of the collapsed lung and aerated lung

Femoral and popliteal veins are assessed for intravascular thrombosis using the two-point compression technique \[[@CR12], [@CR42]\] (Fig. [3](#Fig3){ref-type="fig"}), in which the vein collapsibility is evaluated in two points for each lower extremity: the common femoral vein at the level of the groin and the popliteal vein in the popliteal fossa. A DVT is defined as the inability to completely collapse the vein with the ultrasound probe. This technique has proved a sensitivity of 96.1% and specificity of 96.6% diagnosing proximal DVT when it has been compared to standard vein ultrasound performed by radiologists \[[@CR12], [@CR42]\]. Fig. 3Femoral and popliteal vein POCUS. **a** The *illustration* shows the two points of the lower extremities assessed for DVT: the common femoral vein at the groin level and popliteal vein at the popliteal fossa. **b**, **c** Ultrasound images showing the vein marked with yellow arrows before (**b**) and after (**c**) external compression has been applied. In this case, the vein is entirely collapsible, consistent with absence of a DVT. DVT deep venous thrombosis, POCUS point-of-care ultrasound

Once the test has been performed, a structured report summarizing the main findings is written. The quality of this report is immediately assessed by a second POCUS expert reviewing the images recorded. There are three experts participating in this study as quality evaluators (CR, AR, and DV), all of them with at least 10 years of experience in POCUS. The revised report is given to the treating team without any direction of management, who in turn are requested to fill out forms about their clinical assessment before and after receiving the POCUS report (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Steps involved in the intervention group. In the intervention group, a POCUS of the heart, lungs, and femoral and popliteal veins is performed at the patient's bedside. The report summarizing the main findings is assessed by a second expert in POCUS before it is given to the treating team. The treating team is requested to fill out forms about their clinical assessment and management plan before and after receiving the POCUS report. The difference between forms will be recorded as influence of POCUS. POCUS point-of-care ultrasound

The intervention will not be performed or will be stopped after being already started if the patient refers intolerable discomfort during the procedure or in any clinical condition that involves urgent management such as cardiorespiratory arrest, pain, or respiratory distress. In these cases, if some of the variables were already assessed, a report with partial information will be given to the treating team.

The control group follows the standard care pathway, which does not include POCUS. Diagnosis and management will be based on clinical evaluation and other investigations. Ultrasound examinations are not precluded such as those performed by cardiology or radiology staff, but POCUS of the heart, lungs, or lower extremity veins are not allowed during the time that the participant remains admitted to an internal medicine ward.

There are no restrictions in medication use or further standard investigations in any of the two groups.

Outcomes {#Sec10}
--------

### Primary outcome {#Sec11}

The primary outcome is the difference in the median of length of hospital stay between the intervention group and the control group. Length of stay (LOS) is defined as number of hours from admission to the internal medicine ward to hospital discharge.

### Secondary outcomes {#Sec12}

Impact on diagnosis and management will be reported as follows: (1) number and proportion of patients in whom a new diagnosis was found with POCUS; (2) number and proportion of patients in whom the main cardiorespiratory diagnosis was changed after POCUS; (3) number and proportion of patients who had a management modification. Management includes adding or removing medications to treat cardiorespiratory conditions (e.g. diuretics), requesting further investigations, and consulting to another specialist.

Readmission to the hospital will be presented as proportion of patients readmitted to the hospital during the next 30 days after hospital discharge in both groups.

Healthcare costs involve total costs spent in each patient during their hospital stay presented in Australian dollars. The data will be organized in several categories (bed stay, imaging tests, pathology investigations). The average cost of each category will be compared between groups.

Participant timeline {#Sec13}
--------------------

Screening for eligibility, enrolment, allocation, and intervention is performed on the same day (Fig. [5](#Fig5){ref-type="fig"}). No follow-up of participants is done after hospital discharge. Data about LOS, 30-day readmission, and costs will be obtained from the hospital electronic databases after finishing the recruitment. Fig. 5Schedule of enrolment, intervention, and assessments

Sample size {#Sec14}
-----------

A sample size of 122 participants in each group has been estimated, which is being rounded up to a total of 250 participants to allow withdrawals. This estimation has been calculated using the statistical software G Power Version 3, based on a t-test of log transformed LOS in hours from internal medicine wards of the RMH (median 103 h), a clinically important effect on LOS defined as ≥ 24 h, power of 80%, and alpha of 0.05.

Recruitment {#Sec15}
-----------

One of the investigators (XC) attends every internal medicine handover from Monday to Friday, ensuring that all the new cardiopulmonary patients from the previous night shift are screened for eligibility. Once the internal medicine physicians have identified the potential participants, the order in which these patients will be approached is done following a randomized sequence created by computer software. In this way, selection bias is significantly reduced. Participants received verbally information and a written document about what it means to participate in this study and how the study is conducted. Once they have agreed to participate, they are asked to sign an informed consent form. In case participants cannot give their consent due to cognitive impairment, a person responsible or a person already stablished as their medical treatment decision maker will be asked to sign the consent on their behalf.

The recruitment rate for the past eight months has been 15 participants per month. Therefore, we expect to complete the recruitment in eight months. A proposed of Consolidated Standard of Reporting Trials (CONSORT) flowchart is shown in Fig. [6](#Fig6){ref-type="fig"}. Fig. 6Proposed Consolidated Standard of Reporting Trials (CONSORT) *flow chart* for IMFCU-1 study

Allocation {#Sec16}
----------

Participants are randomly assigned to the intervention or control group with a 1:1 ratio. The allocation sequence is based on permuted blocks of random size, generated by computer software. Blocks sizes are 4, 6, or 8. Sealed, numbered, double-layered, opaque envelopes are used for concealment. The concealment was performed by a non-investigator. Enrolment and allocation will be done by the same investigator after participant has signed the informed consent form. The only person who has access to the allocation sequence is the main investigator, who is not involved in the recruitment process.

Blinding {#Sec17}
--------

Due to the nature of the intervention, blinding was not possible. It was considered unethical to perform POCUS and conceal the results in the control group. However, in order to reduce detection bias, the person assigning the primary outcome will be blinded to what group each participant belongs.

Withdrawal from the study {#Sec18}
-------------------------

If participants withdraw from the study, their data will not be available for analysis. To date this has not occurred and we anticipate a very low withdrawal number.

Data collection methods {#Sec19}
-----------------------

Demographic data and baseline information will be gathered prospectively by one of the investigators from the medical notes. Baseline data is detailed in Table [5](#Tab5){ref-type="table"}. Table 5Patient basal data to be collectedDemographic dataAge (years)Gender (female)Height (cm)Weight (kg)BMI (kg/m^2^)Prior medical conditionsHypertensionCongestive cardiac failureAnginaMyocardial infarctionCoronary interventionKnown significant valve diseaseValve replacementCardiac arrhythmiaPulmonary hypertensionCOPDInterstitial lung diseaseAsthmaSmokingDiabetesKnown renal failureStrokeHIVVenous thromboembolismCancer (type, active/remission, metastasis)Chronic liver diseaseHypothyroidismHyperthyroidismCognitive impairment/dementiaChronic medicationAntihypertensiveBeta-blockersAntiplateletAnticoagulantSystemic steroidsDiureticsChemotherapyOtherCardiopulmonary symptomsDyspnea/shortness of breathChest painPalpitationsCoughFever suspected to be respiratory or cardiacLower limb edemaAltered state of consciousnessOtherVital signsBlood pressure (mmHg)Heart rate (beats per minute)Temperature (°C)Respiratory rate (breaths per minute)O~2~ saturation (%)*BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *HIV* human immunodeficiency virus

### Primary outcome {#Sec20}

Hospital LOS is obtained from the hospital operating system and is not influenced by any of the investigators. A list with full name, patient number, and the date of admission, but blinded to allocation, will be sent to the hospital Business Intelligence Unit to generate the LOS data.

If patients are transferred from physical internal medicine wards to the "Hospital in the Home" (HITH) program, an acute general care program in the patients homes, the LOS will be added to the LOS on internal medicine wards.

### Secondary outcomes {#Sec21}

New diagnosis and change in management will be evaluated using forms about clinical assessment completed by the treating physician before and after the findings of POCUS are revealed to them. Both forms are exactly the same. The difference between them will be interpreted as the effect of the intervention. (Fig. [4](#Fig4){ref-type="fig"}).

The information requested in these forms includes (Additional file [2](#MOESM2){ref-type="media"}): The hemodynamic state of the patients from the following options: normal; hypovolemia; primary diastolic failure; primary systolic failure; systolic and diastolic failure; vasodilation; and RV failure.Describing physical examination findings specifying LV function, significant valve regurgitation or valve stenosis, pericardial effusion, suspicion of PE, abnormalities of the lungs, and evidence of DVT.Recording the most likely diagnosis.Detailing further investigations. In this section they will have a list of pathology tests, imaging tests, and consultations to other medical specialties. They will be asked to mark all the further investigations that they are requesting.Describing the type of treatment prescribed from five options: (1) heart failure treatment (defined by one of the following treatment: diuretics, vasodilators, and/or fluid restriction); (2) COPD/asthma treatment (defined as the use of bronchodilators and/or systemic steroids); (3) antibiotics; (4) anticoagulation in therapeutic dose; and (5) "other" in case it is a different treatment from the four above. More than one option can be chosen.

The seniority of doctors who will complete the forms is restricted to internal medicine specialists and specialist trainees.

Readmission to the hospital data will be gathered from hospital operating system in the same form that has been explained for the primary outcome. Planned readmissions will be excluded, analyzing only unplanned readmissions in the following 30 days after hospital discharge.

Information about economic health will be gathered directly from the Business Intelligence Unit. This unit centralizes all the information related to health costs and analyses it for administrative purposes.

Once the trial has finished recruiting, we will send them the blinded list of patients specifying the admission and discharge date. Hospital costs include total costs and categories such as bed stay, imaging tests, and pathology tests.

### Harms {#Sec22}

Performing POCUS is highly unlikely to cause unintended effects. It is a non-invasive and ionizing radiation-free imaging test with no severe side effects reported other than infrequent patient discomfort \[[@CR50]\]. However, severe bruising from probe manipulation over the skin and patient falls during the procedure set-up (e.g. when a patient is transferred from the chair to their bed) will be documented and reported in the final results as total number of events. If any of these events occur, management will have to refer the event to the treating physician.

Statistical methods {#Sec23}
-------------------

The primary outcome, LOS in hours, will be analyzed using Student's t-test on the log scale, in anticipation of skewness in raw LOS. Log transforming might normalize a skewed data, making outliers unlikely. However, a cut-off of 30 days will be applied to LOS to avoid the effect of extremely long hospital stays. Statistical analysis will be done using the software SPPS (Statistical Package for the Social Sciences), version 26.

For patients who die in hospital, death will be treated as hospital discharge for the primary analysis as the unpublished mortality rate of patients admitted to internal medicine wards of the RMH is low (2.7%). However, a sensitivity analysis will be conducted to explore the impact of this approach. Missing data for the primary outcome are not expected as it is anticipated that LOS will be available for every patient in the study. If for some reason this information is missing, those patients will not be included in the primary statistical analysis.

For the primary outcome, significance is defined as *p* \< 0.05. Secondary outcomes will be analyzed using parametric or non-parametric tests according to the type of data, whether the data are skewed, and whether repeated measures are used. As the secondary endpoints involve more pairwise comparisons, significance will be defined as *p* \< 0.01 to reduce the risk of Type 1 error from multiple pairwise comparisons. All estimates will be reported with 95% confidence intervals. All analysis will be based on the principle of intention-to-treat.

Data management {#Sec24}
---------------

All data will be entered electronically using numerical codes. Paper records will be stored in files in a locked filing cabinet, in a locked room in the Department of Surgery of the University of Melbourne. Electronic data are stored in password-protected databases, available only to researchers involved in the study. The primary outcome and health cost data are generated from the hospital electronic systems and not under the influence of investigators. Other data will undergo double data entry range checks for data value errors.

Due to the small trial size, there is neither Data Monitoring Committee (DMC) established nor stopping rules applied. There is no planned interim analysis.

The final results of this study are intended to be disseminated through publications in peer-reviewed medical journals. After publishing, data about demographic, primary, and secondary outcomes will be shared to other researchers who request it to the principal investigator with a project proposal and with acceptance of release of data by the Melbourne Health Human Research Ethics Committee.

Discussion {#Sec25}
==========

This study will show whether the addition of a multi-organ POCUS in internal medicine patients reduces the LOS at the hospital. LOS was selected as the main outcome as it was considered objective, reliable data and clinically relevant to both the patient and the healthcare system. Demonstrating an impact in LOS will encourage physicians around the world to incorporate this technique in their routinely practice.

The novelty of this study is that it is the first randomized trial assessing the impact on LOS of a multi-organ focused ultrasound in internal medicine. Last year, Mozzini et al. \[[@CR51]\] described a positive impact of repetitive lung ultrasounds on the LOS in patients with heart failure admitted to the internal medicine ward. Based on their results, we are optimistic about finding a positive effect this time assessing a multi-organ focused ultrasound which not only evaluate lung but also heart and DVT.

The limitations of the study are that the outcomes are short-term and related to hospital admission. This study will provide clinical data that can serve to assess feasibility and sample size for a trial investigating morbidity and mortality outcomes. A randomized pilot study investigating focused cardiac ultrasound in patients undergoing fractured neck of femur surgery showed a group separation of 30-day mortality and morbidity outcomes of 39% favoring the use of cardiac ultrasound \[[@CR52]\] and a lower 12-month mortality \[[@CR53]\]. The sample size of this study, however, is too small to investigate morbidity and mortality outcomes for the cardiopulmonary admissions to internal medicine wards. Further, the use of ultrasound in not a medical intervention but rather an investigation. The behavior change consequent on the information is the actual mechanism whereby improved outcomes can occur. If the treating medical staff choose to ignore the findings, or not act appropriately upon them, then the value of the ultrasound examination is diminished. This problem is most likely to occur at the start of the study where skepticism regarding the POCUS study exists and reduces over time as the additional knowledge form a feedback loop on the clinician's diagnostic approach.

Trial status {#Sec26}
============

Recruiting.

Recruitment began on 3 September 2018.

Supplementary information
=========================

 {#Sec27}

**Additional file 1.** SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents. **Additional file 2.** Clinical Assessment.

A4C

:   Apical four chambers

COPD

:   Chronic obstructive pulmonary disease

DVT

:   Deep venous thrombosis

LA

:   Left atrium

LOS

:   Length of stay

LV

:   Left ventricle

LVEDA

:   Left ventricle end-diastole area

LVEDD

:   Left ventricle end-diastole diameter

LVESA

:   Left ventricle end-systole area

LVESD

:   Left ventricle end-systole diameter

PE

:   Pulmonary embolism

PLAX

:   Parasternal long axis

POCUS

:   Point-of-care ultrasound

PSAX

:   Parasternal short axis

RMH

:   Royal Melbourne Hospital

RV

:   Right ventricle

RVEDD

:   Right ventricle end-diastole diameter
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